Arnold joins the Dutch insulin pump maker with nearly 25 years of leadership experience in medtech and diabetes. His track record includes spearheading commercialization initiatives, business strategy and product launches for medical device companies.
Before taking the corner office at ViCentra, Arnold held leadership roles at Medtronic, Procept BioRobotics, Boston Scientific and Sorin Group. Most recently, he served as VP of global marketing at Procept. Before that, he was VP of commercial strategy and enablement at Medtronic.
While at Medtronic, he played a pivotal role in launching the world’s first hybrid closed-loop insulin pump system, ViCentra said.
Arnold also has a personal connection with diabetes management. His youngest daughter was diagnosed with type 1 diabetes at 11 months old and has worn an insulin pump for 17 years.
“Tom’s extensive experience in commercial strategy, his deep knowledge of the healthcare sector, and personal connection to the diabetes community make him uniquely qualified to lead ViCentra into its next phase of growth,” said Jan Keltjens, chair of the board at ViCentra. “I am pleased to welcome Tom to the ViCentra team as we position ViCentra to accelerate growth, broaden access to Kaleido and make life with diabetes more personal and simpler.”
More about ViCentra Kaleido as a new CEO takes over
Arnold comes to ViCentra as the company looks to drive growth for its Kaleido system. The company aims to deliver high-quality, user-friendly solutions for people with diabetes. Kaleido features pulse technology that provides continuous micro-dosing of insulin.
Kaleido offers users options in terms of wearability and comes with two durable, rechargeable pumps, eliminating the need to dispose of the pump every three days, while the infusion set lasts for that three-day span. The design aims to integrate seamlessly into the user’s daily life.
Users can choose between a short tube for placement as a patch directly on the body or a longer tube for carrying the pump in the pocket. They can pause or take the pump off for intermittent breaks, too. ViCentra designed 10 bright color options as well, giving customers a more personal choice.
ViCentra launched its hybrid closed-loop automated insulin delivery system that uses the Dexcom G6 CGM in 2023. The company won CE mark approval for Kaleido last fall. ViCentra said it has approximately 2,500 active users across the Netherlands, France and Germany. It plans to expand its international commercialization activities under Arnold’s stewardship.
“As both a MedTech leader and a father, I understand the impact that well-designed, intuitive technology can have on diabetes management. Kaleido’s approach to making insulin therapy more flexible, discreet, and empowering resonates deeply with me,” said Arnold. “I am honored to lead ViCentra at such an exciting time to help drive meaningful progress for the diabetes community.”
